Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts

Journal of Infection

Volumn 55, Issue 4, 2007, Pages 287-299

  Metcalf, S C ^a   Dockrell, D H ^a,b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amphotericin B; Caspofungin; Invasive fungal infection; Posaconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ATORVASTATIN; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CORTICOSTEROID; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; HALOFANTRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MEVINOLIN; MICAFUNGIN; PHENYTOIN; POSACONAZOLE; PYRROLE DERIVATIVE; QUINIDINE; RAPAMYCIN; RIFAMPICIN; SIMVASTATIN; SULFONYLUREA; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFUSION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; IMMUNE DEFICIENCY; IN VITRO STUDY; INFECTION PREVENTION; INJECTION SITE REACTION; LIVER FUNCTION TEST; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PHOTOPHOBIA; PNEUMONIA; QT PROLONGATION; REVIEW; SALVAGE THERAPY; SIDE EFFECT; THROMBOPHLEBITIS; TREATMENT OUTCOME; VISUAL DISORDER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; DRUG COMBINATIONS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; PEPTIDES, CYCLIC; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; TREATMENT OUTCOME;

EID: 34548494827     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.06.012     Document Type: Review

References (154)

1. Patterson T.F. Advances and challenges in management of invasive mycoses. Lancet 366 9490 (2005) 1013-1025
2. Wald A., Leisenring W., van Burik J.A., and Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175 6 (1997) 1459-1466
3. Caillot D., Casasnovas O., Bernard A., Couaillier J.F., Durand C., Cuisenier B., et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15 1 (1997) 139-147
4. von Eiff M., Roos N., Schulten R., Hesse M., Zuhlsdorf M., and van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Resp Int Rev Thorac Dis 62 6 (1995) 341-347
5. Pound M.W., Drew R.H., and Perfect J.R. Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis 15 2 (2002) 183-194
6. Ruhnke M., and Maschmeyer G. Management of mycoses in patients with hematologic disease and cancer review of the literature. Eur J Med Res 7 5 (2002) 227-235
7. Pizzo P.A., Robichaud K.J., Gill F.A., and Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 1 (1982) 101-111
8. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 86 6 Pt 1 (1989) 668-672
9. Shaukat A., Bakri F., Young P., Hahn T., Ball D., Baer M.R., et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 159 2 (2005) 181-188
10. Segal B.H., Almyroudis N.G., Battiwalla M., Herbrecht R., Perfect J.R., Walsh T.J., et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44 3 (2007) 402-409
11. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., Chamilos G., Healy M., Perego C., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191 8 (2005) 1350-1360
12. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 4 (2007) 335-347
13. Maertens J., Verhaegen J., Lagrou K., Van Eldere J., and Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97 6 (2001) 1604-1610
14. Obayashi T., Yoshida M., Mori T., Goto H., Yasuoka A., Iwasaki H., et al. Plasma (1→3)-beta-d-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345 8941 (1995) 17-20
15. Lin M.T., Lu H.C., and Chen W.L. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 33 10 (2001) 1621-1627
16. White P.L., Linton C.J., Perry M.D., Johnson E.M., and Barnes R.A. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 42 4 (2006) 479-486
17. Caillot D., Couaillier J.F., Bernard A., Casasnovas O., Denning D.W., Mannone L., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19 1 (2001) 253-259
18. Greene R.E., Schlamm H.T., Oestmann J.W., Stark P., Durand C., Lortholary O., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44 3 (2007) 373-379
19. Maertens J., Theunissen K., Verhoef G., Verschakelen J., Lagrou K., Verbeken E., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 9 (2005) 1242-1250
20. De Pauw B.E. New antifungal agents and preparations. Int J Antimicrob Agents 16 2 (2000) 147-150
21. Bates D.W., Su L., Yu D.T., Chertow G.M., Seger D.L., Gomes D.R., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32 5 (2001) 686-693
22. Ullmann A.J., Sanz M.A., Tramarin A., Barnes R.A., Wu W., Gerlach B.A., et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 43 4 (2006) e29-e38
23. Dix S.P., and Andriole V.T. Lipid formulations of Amphotericin B. Curr Clin Topics Infect Dis 20 (2000) 1-23
24. Wasan K.M., and Lopez-Berestein G. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J Drug Target 2 5 (1994) 373-380
25. Takemoto K., Yamamoto Y., Ueda Y., Sumita Y., Yoshida K., and Niki Y. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 57 4 (2006) 724-731
26. Groll A.H., Lyman C.A., Petraitis V., Petraitiene R., Armstrong D., Mickiene D., et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 50 10 (2006) 3418-3423
27. Wingard J.R., White M.H., Anaissie E., Raffalli J., Goodman J., and Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31 5 (2000) 1155-1163
28. Johnson P.C., Wheat L.J., Cloud G.A., Goldman M., Lancaster D., Bamberger D.M., et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137 2 (2002) 105-109
29. Stevens D.A., Kan V.L., Judson M.A., Morrison V.A., Dummer S., Denning D.W., et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30 4 (2000) 696-709
30. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340 10 (1999) 764-771
31. Walsh T.J., Goodman J.L., Pappas P., Bekersky I., Buell D.N., Roden M., et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45 12 (2001) 3487-3496
32. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44 10 (2007) 1289-1297
33. Boogaerts M., and Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 61 Suppl. 1 (2001) 39-47
34. Mohr J.F., Finkel K.W., Rex J.H., Rodriguez J.R., Leitz G.J., and Ostrosky-Zeichner L. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother 48 8 (2004) 3151-3153
35. Winston D.J., Maziarz R.T., Chandrasekar P.H., Lazarus H.M., Goldman M., Blumer J.L., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138 9 (2003) 705-713
36. Marr K.A., Crippa F., Leisenring W., Hoyle M., Boeckh M., Balajee S.A., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 4 (2004) 1527-1533
37. Harousseau J.L., Dekker A.W., Stamatoullas-Bastard A., Fassas A., Linkesch W., Gouveia J., et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44 7 (2000) 1887-1893
38. Mattiuzzi G.N., Kantarjian H., O'Brien S., Kontoyiannis D.P., Giles F., Zhou X., et al. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100 3 (2004) 568-573
39. Boogaerts M., Winston D.J., Bow E.J., Garber G., Reboli A.C., Schwarer A.P., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135 6 (2001) 412-422
40. Caillot D., Bassaris H., McGeer A., Arthur C., Prentice H.G., Seifert W., et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33 8 (2001) e83-e90
41. Phillips P., Zemcov J., Mahmood W., Montaner J.S., Craib K., and Clarke A.M. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS (London, England) 10 12 (1996) 1369-1376
42. Cimerman S., Sokolowski W., Goncalves S.E., Lins M.S., and Colombo A.L. Case report. Histoplasmosis in an AIDS paediatric patient. Mycoses 42 9-10 (1999) 567-569
43. Denning D.W., Riniotis K., Dobrashian R., and Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37 Suppl. 3 (2003) S265-S280
44. Sabo J.A., and Abdel-Rahman S.M. Voriconazole: a new triazole antifungal. Ann Pharmacother 34 9 (2000) 1032-1043
45. Ghannoum M.A., and Kuhn D.M. Voriconazole better chances for patients with invasive mycoses. Eur J Med Res 7 5 (2002) 242-256
46. Johnson L.B., and Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36 5 (2003) 630-637
47. Capitano B., Potoski B.A., Husain S., Zhang S., Paterson D.L., Studer S.M., et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 50 5 (2006) 1878-1880
48. von Mach M.A., Burhenne J., and Weilemann L.S. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 6 (2006) 6
49. Trifilio S., Ortiz R., Pennick G., Verma A., Pi J., Stosor V., et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35 5 (2005) 509-513
50. Boyd A.E., Modi S., Howard S.J., Moore C.B., Keevil B.G., and Denning D.W. Adverse reactions to voriconazole. Clin Infect Dis 39 8 (2004) 1241-1244
51. Denning D.W., and Griffiths C.E. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26 8 (2001) 648-653
52. Alkan Y., Haefeli W.E., Burhenne J., Stein J., Yaniv I., and Shalit I. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 39 6 (2004) e49-e52
53. den Hollander J.G., van Arkel C., Rijnders B.J., Lugtenburg P.J., de Marie S., and Levin M.D. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 57 6 (2006) 1248-1250
54. McGinnis M.R., Pasarell L., Sutton D.A., Fothergill A.W., Cooper Jr. C.R., and Rinaldi M.G. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 41 8 (1997) 1832-1834
55. Murphy M., Bernard E.M., Ishimaru T., and Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 41 3 (1997) 696-698
56. Sanati H., Belanger P., Fratti R., and Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 41 11 (1997) 2492-2496
57. Paphitou N.I., Ostrosky-Zeichner L., Paetznick V.L., Rodriguez J.R., Chen E., and Rex J.H. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 46 10 (2002) 3298-3300
58. Diekema D.J., Messer S.A., Hollis R.J., Jones R.N., and Pfaller M.A. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41 8 (2003) 3623-3626
59. Gil-Lamaignere C., Roilides E., Mosquera J., Maloukou A., and Walsh T.J. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 46 7 (2002) 2234-2237
60. Ruhnke M., Schmidt-Westhausen A., and Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41 3 (1997) 575-577
61. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 9495 (2005 Oct 22-28) 1435-1442
62. Ally R., Schurmann D., Kreisel W., Carosi G., Aguirrebengoa K., Dupont B., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33 9 (2001) 1447-1454
63. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 6 (2002) 408-415
64. Patterson T.F., Boucher H.W., Herbrecht R., Denning D.W., Lortholary O., Ribaud P., et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 41 10 (2005) 1448-1452
65. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 5 (2002) 563-571
66. Perfect J.R., Marr K.A., Walsh T.J., Greenberg R.N., DuPont B., de la Torre-Cisneros J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 9 (2003) 1122-1131
67. Baden L.R., Katz J.T., Fishman J.A., Koziol C., DelVecchio A., Doran M., et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 76 11 (2003) 1632-1637
68. Steinbach W.J., Benjamin Jr. D.K., Kontoyiannis D.P., Perfect J.R., Lutsar I., Marr K.A., et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 39 2 (2004) 192-198
69. Sambatakou H., Dupont B., Lode H., and Denning D.W. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 119 6 (2006) e17-e24 [527]
70. Schwartz S., Ruhnke M., Ribaud P., Corey L., Driscoll T., Cornely O.A., et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106 8 (2005) 2641-2645
71. Mouas H., Lutsar I., Dupont B., Fain O., Herbrecht R., Lescure F.X., et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40 8 (2005) 1141-1147
72. Wenzel R., Del Favero A., Kibbler C., Rogers T., Rotstein C., Mauskopf J., et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 55 3 (2005) 352-361
73. Walsh T.J., Pappas P., Winston D.J., Lazarus H.M., Petersen F., Raffalli J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 4 (2002) 225-234
74. Walsh T.J., Lutsar I., Driscoll T., Dupont B., Roden M., Ghahramani P., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21 3 (2002) 240-248
75. Vigouroux S., Morin O., Moreau P., Mechinaud F., Morineau N., Mahe B., et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 40 4 (2005) e35-e37
76. Krieter P., Flannery B., Musick T., Gohdes M., Martinho M., and Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 48 9 (2004) 3543-3551
77. Ullmann A.J., Cornely O.A., Burchardt A., Hachem R., Kontoyiannis D.P., Topelt K., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 50 2 (2006) 658-666
78. Courtney R., Wexler D., Radwanski E., Lim J., and Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57 2 (2004) 218-222
79. Wexler D., Courtney R., Richards W., Banfield C., Lim J., and Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 21 5 (2004) 645-653
80. Gubbins P.O., Krishna G., Sansone-Parsons A., Penzak S.R., Dong L., Martinho M., et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 50 6 (2006) 1993-1999
81. Raad II, Graybill J.R., Bustamante A.B., Cornely O.A., Gaona-Flores V., Afif C., et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 42 12 (2006) 1726-1734
82. Munayyer H.K., Mann P.A., Chau A.S., Yarosh-Tomaine T., Greene J.R., Hare R.S., et al. Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother 48 10 (2004) 3690-3696
83. Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C., Hare R., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50 6 (2006) 2009-2015
84. van Burik J.A., Hare R.S., Solomon H.F., Corrado M.L., and Kontoyiannis D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42 7 (2006) e61-e65
85. Raad I.I., Hachem R.Y., Herbrecht R., Graybill J.R., Hare R., Corcoran G., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42 10 (2006) 1398-1403
86. Graybill J.R., Najvar L.K., Johnson E., Bocanegra R., and Loebenberg D. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother 48 6 (2004) 2288-2291
87. Negroni R., Helou S.H., Petri N., Robles A.M., Arechavala A., and Bianchi M.H. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 38 3 (2004) e15-e20
88. Wheat L.J., Connolly P., Smedema M., Durkin M., Brizendine E., Mann P., et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 57 6 (2006) 1235-1239
89. Anstead G.M., Corcoran G., Lewis J., Berg D., and Graybill J.R. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 40 12 (2005) 1770-1776
90. Pitisuttithum P., Negroni R., Graybill J.R., Bustamante B., Pappas P., Chapman S., et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56 4 (2005) 745-755
91. Vazquez J.A., Skiest D.J., Nieto L., Northland R., Sanne I., Gogate J., et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42 8 (2006) 1179-1186
92. Vazquez J.A., and Sobel J.D. Anidulafungin: a novel echinocandin. Clin Infect Dis 43 2 (2006) 215-222
93. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill R., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 1 (2007) 2-12
94. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 4 (2007) 348-359
95. De Pauw B.E., and Donnelly J.P. Prophylaxis and aspergillosis-has the principle been proven?. N Engl J Med 356 4 (2007) 409-411
96. Denning D.W. Echinocandins: a new class of antifungal. J Antimicrob Chemother 49 6 (2002) 889-891
97. Denning D.W. Echinocandin antifungal drugs. Lancet 362 9390 (2003) 1142-1151
98. Jarvis B., Figgitt D.P., and Scott L.J. Micafungin. Drugs 64 9 (2004) 969-982 [discussion 83-4]
99. Krause D.S., Reinhardt J., Vazquez J.A., Reboli A., Goldstein B.P., Wible M., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 48 6 (2004) 2021-2024
100. Bennett J.E. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 355 11 (2006) 1154-1159
101. Cleary J.D., Schwartz M., Rogers P.D., de Mestral J., and Chapman S.W. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 23 8 (2003) 966-973
102. Nguyen T.H., Hoppe-Tichy T., Geiss H.K., Rastall A.C., Swoboda S., Schmidt J., et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 60 1 (2007) 100-106
103. Chandrasekar P.H., and Sobel J.D. Micafungin: a new echinocandin. Clin Infect Dis 42 8 (2006) 1171-1178
104. Bachmann S.P., Patterson T.F., and Lopez-Ribot J.L. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 40 6 (2002) 2228-2230
105. Bartizal K., Gill C.J., Abruzzo G.K., Flattery A.M., Kong L., Scott P.M., et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 41 11 (1997) 2326-2332
106. Del Poeta M., Schell W.A., and Perfect J.R. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 41 8 (1997) 1835-1836
107. Feldmesser M., Kress Y., Mednick A., and Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 182 6 (2000) 1791-1795
108. Barchiesi F., Spreghini E., Tomassetti S., Della Vittoria A., Arzeni D., Manso E., et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 50 8 (2006) 2719-2727
109. Posteraro B., Sanguinetti M., Fiori B., La Sorda M., Spanu T., Sanglard D., et al. Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. J Antimicrob Chemother 58 2 (2006) 458-461
110. Balashov S.V., Park S., and Perlin D.S. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50 6 (2006) 2058-2063
111. Hakki M., Staab J.F., and Marr K.A. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50 7 (2006) 2522-2524
112. Moudgal V., Little T., Boikov D., and Vazquez J.A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49 2 (2005) 767-769
113. Oakley K.L., Moore C.B., and Denning D.W. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 42 10 (1998) 2726-2730
114. Odds F.C., Motyl M., Andrade R., Bille J., Canton E., Cuenca-Estrella M., et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 42 8 (2004) 3475-3482
115. Andes D., Marchillo K., Lowther J., Bryskier A., Stamstad T., and Conklin R. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 47 4 (2003) 1187-1192
116. Bowman J.C., Hicks P.S., Kurtz M.B., Rosen H., Schmatz D.M., Liberator P.A., et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 46 9 (2002) 3001-3012
117. Soustre J., Rodier M.H., Imbert-Bouyer S., Daniault G., and Imbert C. Caspofungin modulates in vitro adherence of Candida albicans to plastic coated with extracellular matrix proteins. J Antimicrob Chemother 53 3 (2004) 522-525
118. Shuford J.A., Rouse M.S., Piper K.E., Steckelberg J.M., and Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 194 5 (2006) 710-713
119. Villanueva A., Gotuzzo E., Arathoon E., Noriega L., Kartsonis N., Lupinacci R., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113 4 (2002) 294
120. Villanueva A., Arathoon E.G., Gotuzzo E., Berman R.S., DiNubile M.J., and Sable C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33 9 (2001) 1529-1535
121. Arathoon E.G., Gotuzzo E., Noriega L.M., Berman R.S., DiNubile M.J., and Sable C.A. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46 2 (2002) 451-457
122. Colombo A.L., Perfect J., DiNubile M., Bartizal K., Motyl M., Hicks P., et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22 8 (2003) 470-474
123. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 25 (2002) 2020-2029
124. Glasmacher A., Cornely O.A., Orlopp K., Reuter S., Blaschke S., Eichel M., et al. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J Antimicrob Chemother 57 1 (2006) 127-134
125. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 11 (2004) 1563-1571
126. Kartsonis N.A., Saah A.J., Joy Lipka C., Taylor A.F., and Sable C.A. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 50 3 (2005) 196-205
127. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 14 (2004) 1391-1402
128. Mattiuzzi G.N., Alvarado G., Giles F.J., Ostrosky-Zeichner L., Cortes J., O'Brien S., et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50 1 (2006) 143-147
129. de Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della Negra M., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39 6 (2004) 842-849
130. Krause D.S., Simjee A.E., van Rensburg C., Viljoen J., Walsh T.J., Goldstein B.P., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39 6 (2004) 770-775
131. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 9572 (2007) 1519-1527
132. Reboli A., Rotstein C., Pappas P., et al. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC) (2005), American Society for Microbiology, Washington, DC [abstract 1040]
133. Denning D.W., Marr K.A., Lau W.M., Facklam D.P., Ratanatharathorn V., Becker C., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53 5 (2006) 337-349
134. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 10 (2004) 1407-1416
135. Kontoyiannis D.P., and Lewis R.E. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 126 2 (2004) 165-175
136. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52 1 (2003) 1
137. Saag M.S., Graybill R.J., Larsen R.A., Pappas P.G., Perfect J.R., Powderly W.G., et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30 4 (2000) 710-718
138. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 2 (2004) 161-189
139. Steinbach W.J., Stevens D.A., and Denning D.W. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 37 Suppl. 3 (2003) S188-S224
140. Rex J.H., Pappas P.G., Karchmer A.W., Sobel J., Edwards J.E., Hadley S., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 10 (2003) 1221-1228
141. Rex J.H., Walsh T.J., Sobel J.D., Filler S.G., Pappas P.G., Dismukes W.E., et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30 4 (2000) 662-678
142. Barchiesi F., Spreghini E., Tomassetti S., Giannini D., and Scalise G. Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob Agents Chemother 51 3 (2007) 941-945
143. Aliff T.B., Maslak P.G., Jurcic J.G., Heaney M.L., Cathcart K.N., Sepkowitz K.A., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97 4 (2003) 1025-1032
144. Kontoyiannis D.P., Hachem R., Lewis R.E., Rivero G.A., Torres H.A., Thornby J., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 2 (2003) 292-299
145. Marr K.A., Boeckh M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 6 (2004) 797-802
146. Maertens J., Glasmacher A., Herbrecht R., Thiebaut A., Cordonnier C., Segal B.H., et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107 12 (2006) 2888-2897
147. Denning D.W. Invasive aspergillosis. Clin Infect Dis 26 4 (1998) 781-803 [quiz 4-5]
148. Steinbach W.J., and Stevens D.A. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37 Suppl. 3 (2003) S157-S187
149. Pappas P.G., Bustamante B., Ticona E., Hamill R.J., Johnson P.C., Reboli A., et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 189 12 (2004) 2185-2191
150. Pachl J., Svoboda P., Jacobs F., Vandewoude K., van der Hoven B., Spronk P., et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42 10 (2006) 1404-1413
151. Herbrecht R., Fohrer C., and Nivoix Y. Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 43 8 (2006) 1083 [author reply -4]
152. Cowen L.E., and Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309 5744 (2005) 2185-2189
153. Bennett J.E. Salvage therapy for aspergillosis. Clin Infect Dis 41 Suppl. 6 (2005) S387-S388
154. Raad I., Chapman S., Bradsher R., Morrison V., Goldman M., Graybill J., et al. Posoconazole salvage therapy for invasive fungal infections. Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC) (2004), American Society for Microbiology, Washington, DC [Abstract M-669]